Prevalence of insulin as a first‐line therapy and associated factors in people with type 2 diabetes in German primary care practices

2020 ◽  
Vol 37 (8) ◽  
pp. 1333-1339
Author(s):  
L. Boom ◽  
M. Kaiser ◽  
K. Kostev
Keyword(s):  
Type 2 Diabetes ◽  
Primary Care ◽  
Associated Factors ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Care Practices ◽  
Primary Care Practices

Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted?

Diabetes Care ◽  
2008 ◽  
Vol 31 (Supplement 2) ◽  
pp. S136-S139 ◽  
Author(s):  
E. Standl ◽  
O. Schnell
Keyword(s):  
Type 2 Diabetes ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes

2009 ◽  
Vol 25 (9) ◽  
pp. 2239-2249 ◽  
Author(s):  
Michael R. Jones ◽  
Sunder Mudaliar ◽  
Eric Hernandez-Triana ◽  
Ambika G. Unnikrishnan ◽  
Yu-Ling Lai ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Characteristics and treatment patterns of patients with type 2 diabetes in Lebanon: the DISCOVER study

2021 ◽  
Vol 27 (5) ◽  
pp. 509-515
Author(s):  
Sami T. Azar ◽  
Akram Echtay ◽  
Mireille Amm ◽  
Hajar Ballout ◽  
Iskandar Cheaib ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Practice ◽  
Glycaemic Control ◽  
Treatment Patterns ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
First Line Therapy ◽  
Line Therapy

Background: Lebanon is part of the global DISCOVER study, a global, noninterventional, multicentre, prospective study with 3-years of follow-up. Aims: The aim of this study is to describe real-world clinical practice in terms of type 2 diabetes mellitus (T2DM) disease management and treatment patterns within Lebanon. Methods: Baseline demographic and clinical parameters were captured on a standardized case report form, according to routine clinical practice at each clinical site. Results: We recruited 348 patients. At the initiation of second-line therapy, mean duration of diabetes was 6.7 [standard deviation (SD) 6.5] years; mean HbA1c and fasting plasma glucose levels were 8.5% (SD 1.6%) and 178.7 (SD 56.5) mg/dL respectively. Almost half the patients were hypertensive (45.1%) or had dyslipidaemia (48.6%). Metformin monotherapy was used as first-line therapy in 56.9% of the patients and upfront dual therapy in 25%. The primary reason for changing first-line therapy was poor glycaemic control. The main factors in choosing the second-line therapy were efficacy, tolerability and hypoglycaemia. Conclusion: Clinical inertia was evident in this cohort of patients as they had suboptimal glycaemic control at the time of enrolment and the initiation of second-line therapy. Treatment intensification is required to reduce diabetes-related adverse outcomes.

Sign in / Sign up

Export Citation Format

Share Document